ESSA Pharma Inc

NASDAQ EPIX

Download Data

ESSA Pharma Inc Short-Term Debt to Total Assets Ratio 3 year CAGR for the quarter ending March 31, 2024: 17.58%

ESSA Pharma Inc Short-Term Debt to Total Assets Ratio 3 year CAGR is 17.58% for the quarter ending March 31, 2024, a 151.81% change year over year. The short-term debt to total assets ratio measures the proportion of short-term debt to total assets of a company. It is calculated by dividing the short-term debt by the total assets. This ratio indicates the extent to which short-term debt contributes to the company's total asset structure. A higher ratio suggests a higher level of short-term debt relative to total assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • ESSA Pharma Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2023 was 0.00, a 12.63% change year over year.
  • ESSA Pharma Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2022 was 0.00, a 56.55% change year over year.
  • ESSA Pharma Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2021 was 0.00, a -83.64% change year over year.
  • ESSA Pharma Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2020 was 0.00, a -99.08% change year over year.
NASDAQ: EPIX

ESSA Pharma Inc

CEO Dr. David Ross Parkinson M.D.
IPO Date July 9, 2015
Location Canada
Headquarters 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Employees 50
Sector Healthcare
Industry Biotechnology
Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

StockViz Staff

September 19, 2024

Any question? Send us an email